FAQ on Clene's Direct Offerings and Private Placements

What is Clene Inc. announcing?

Clene Inc. is announcing a series of direct offerings and concurrent private placements, including the issue and sale of 742,626 shares of common stock or prefunded warrants, aiming to raise an estimated $7.3 million.

Why is Clene Inc. raising funds?

The funds raised are intended to support Clene’s mission of improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis.

How is Clene Inc. conducting these offerings?

Clene is conducting these offerings through a securities purchase agreement with a healthcare-focused institutional investor and additional agreements with current investors, directors, and officers of Clene, with Canaccord Genuity acting as the sole placement agent.

When are the offerings expected to close?

The offerings are expected to close on or about October 1, 2024.

Who is involved in these offerings?

A healthcare-focused institutional investor, current investors, directors, and officers of Clene are involved, with Canaccord Genuity serving as the sole placement agent.

What is CNM-Au8?

CNM-Au8 is an investigational, first-in-class therapy developed by Clene that targets mitochondrial function and the NAD pathway to improve the survival and function of central nervous system cells, while reducing oxidative stress.

Where can I find more information about Clene Inc.?

More information about Clene Inc. can be found on their website at www.Clene.com and the full press release is available at https://ibn.fm/oi5IH.

What are the implications of these offerings for investors?

These offerings provide investors with an opportunity to support Clene’s innovative treatments for neurodegenerative diseases, potentially contributing to advancements in mitochondrial health and neuronal function protection.

How does Clene’s approach compare to alternatives?

Clene’s approach focuses on improving mitochondrial health and protecting neuronal function through CNM-Au8, a first-in-class therapy that targets the NAD pathway, offering a novel mechanism compared to traditional treatments for neurodegenerative diseases.

Who should I contact for more information about the offerings?

For more information, you can contact IBN (InvestorBrandNetwork) at Editor@InvestorBrandNetwork.com or visit their website at https://www.InvestorBrandNetwork.com.